CN114173767A - 布洛芬和对乙酰氨基酚的新型组合物 - Google Patents

布洛芬和对乙酰氨基酚的新型组合物 Download PDF

Info

Publication number
CN114173767A
CN114173767A CN202080055146.XA CN202080055146A CN114173767A CN 114173767 A CN114173767 A CN 114173767A CN 202080055146 A CN202080055146 A CN 202080055146A CN 114173767 A CN114173767 A CN 114173767A
Authority
CN
China
Prior art keywords
composition
present
weight
ibuprofen
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080055146.XA
Other languages
English (en)
Chinese (zh)
Inventor
C·D·安德鲁斯
D·E·凯尔斯泰因
K·S·金特
B·R·肖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Haleon US Holdings LLC
Original Assignee
GlaxoSmithKline Consumer Healthcare Holdings US LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=73543315&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN114173767(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GlaxoSmithKline Consumer Healthcare Holdings US LLC filed Critical GlaxoSmithKline Consumer Healthcare Holdings US LLC
Publication of CN114173767A publication Critical patent/CN114173767A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN202080055146.XA 2019-06-27 2020-06-24 布洛芬和对乙酰氨基酚的新型组合物 Pending CN114173767A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962867683P 2019-06-27 2019-06-27
US62/867,683 2019-06-27
PCT/US2020/039321 WO2020263947A1 (en) 2019-06-27 2020-06-24 Novel ibuprofen and acetaminophen composition

Publications (1)

Publication Number Publication Date
CN114173767A true CN114173767A (zh) 2022-03-11

Family

ID=73543315

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080055146.XA Pending CN114173767A (zh) 2019-06-27 2020-06-24 布洛芬和对乙酰氨基酚的新型组合物

Country Status (13)

Country Link
US (3) US11918693B2 (https=)
EP (1) EP3989944A1 (https=)
JP (2) JP7703220B2 (https=)
KR (1) KR20220027194A (https=)
CN (1) CN114173767A (https=)
AU (2) AU2020301401B2 (https=)
BR (1) BR112021026407A8 (https=)
CA (1) CA3143724A1 (https=)
CO (1) CO2021017722A2 (https=)
IL (1) IL288989A (https=)
MX (1) MX2021016089A (https=)
PH (1) PH12021553169A1 (https=)
WO (1) WO2020263947A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7750663B2 (ja) * 2021-03-19 2025-10-07 エスエス製薬株式会社 被覆固形医薬製剤
WO2025212049A1 (en) * 2024-03-30 2025-10-09 Humanis Sağlik A.Ş. Solid pharmaceutical compositions comprising ibuprofen and paracetamol
WO2025212048A1 (en) * 2024-03-30 2025-10-09 Humanis Sağlik A.Ş. Pharmaceutical compositions comprising ibuprofen and paracetamol and relevant excipients

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757090A (en) * 1986-07-14 1988-07-12 Mallinckrodt, Inc. Direct tableting acetaminophen compositions
WO2006004449A2 (en) * 2004-07-07 2006-01-12 Aft Pharmaceuticals Limited A combination composition
PL195966B1 (pl) * 2001-02-23 2007-11-30 Zaklady Farmaceutyczne Polfa L Preparat farmaceutyczny przeciwbólowy
US20090142392A1 (en) * 2005-09-22 2009-06-04 Reckitt Benckiser Healthcare (Uk) Limited Composition Comprising a NSAID and Paracetamol
CN101584673A (zh) * 2009-07-13 2009-11-25 浙江京新药业股份有限公司 一种左乙拉西坦片剂及其制备方法
CN102266301A (zh) * 2011-07-27 2011-12-07 蚌埠丰原涂山制药有限公司 一种非甾体抗炎药片及其制备方法
AU2016210691A1 (en) * 2015-08-05 2017-02-23 Beximco Pharmaceuticals Controlled release formulations of paracetamol
WO2019108147A1 (en) * 2017-11-29 2019-06-06 İlko İlaç Sanayi̇ Ve Ti̇caret A.Ş. Color stable fixed dose tablet combination of ibuprofen and paracetamol

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL104904B1 (pl) 1977-02-11 1979-09-29 Zaklady Radiowe Radmor Sposob wytwarzania anteny z izolacyjna oslona z tworzyw sztucznych
US20080166407A1 (en) * 2005-07-29 2008-07-10 Shalaby Shalaby W Solid oral formulations for combination therapy
CN114681324B (zh) * 2017-07-10 2024-05-03 盖尔凯普科技有限公司 双释放剂型胶囊及其制备方法、装置和系统
US20190350883A1 (en) 2018-05-20 2019-11-21 Luan Chau Pharmaceutical Composition of Acetaminophen/Ibuprofen
US11197830B2 (en) * 2019-02-27 2021-12-14 Aft Pharmaceuticals Limited Pharmaceutical composition containing acetaminophen and ibuprofen

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757090A (en) * 1986-07-14 1988-07-12 Mallinckrodt, Inc. Direct tableting acetaminophen compositions
PL195966B1 (pl) * 2001-02-23 2007-11-30 Zaklady Farmaceutyczne Polfa L Preparat farmaceutyczny przeciwbólowy
WO2006004449A2 (en) * 2004-07-07 2006-01-12 Aft Pharmaceuticals Limited A combination composition
US20090142392A1 (en) * 2005-09-22 2009-06-04 Reckitt Benckiser Healthcare (Uk) Limited Composition Comprising a NSAID and Paracetamol
CN101584673A (zh) * 2009-07-13 2009-11-25 浙江京新药业股份有限公司 一种左乙拉西坦片剂及其制备方法
CN102266301A (zh) * 2011-07-27 2011-12-07 蚌埠丰原涂山制药有限公司 一种非甾体抗炎药片及其制备方法
AU2016210691A1 (en) * 2015-08-05 2017-02-23 Beximco Pharmaceuticals Controlled release formulations of paracetamol
WO2019108147A1 (en) * 2017-11-29 2019-06-06 İlko İlaç Sanayi̇ Ve Ti̇caret A.Ş. Color stable fixed dose tablet combination of ibuprofen and paracetamol

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
DAN BURNETT: "Correlating drug-binder adhesive strengths measured using inverse gas chromatography with tablet performance", 《SURFACE MEASUREMENT SYSTEMS》, pages 1 *
DAN BURNETT: "Correlating drugbinder adhesive strengths measured using Inverse Gas Chromatography with tablet performance", 《SURFACE MEASUREMENT SYSTEMS---IGC SEA CASE STUDY 603》 *
DAN BURNETT: "Correlating drugbinder adhesive strengths measured using Inverse Gas Chromatography with tablet performance", 《SURFACE MEASUREMENT SYSTEMS---IGC SEA CASE STUDY 603》, 22 July 2014 (2014-07-22), pages 1 - 4 *
MARIAM VBAMIUNOMHENE LAWAL ET AL.: "Effect of thermal and chemical modifications on the mechanical and release properties of paracetamol tablet formulations containing corn, cassava and sweet potato starches as filler-binders", 《ASIAN PACIFIC JOURNAL OF TROPICAL BIOMEDICINE》 *
MARIAM VBAMIUNOMHENE LAWAL ET AL.: "Effect of thermal and chemical modifications on the mechanical and release properties of paracetamol tablet formulations containing corn, cassava and sweet potato starches as filler-binders", 《ASIAN PACIFIC JOURNAL OF TROPICAL BIOMEDICINE》, vol. 5, no. 7, 13 June 2015 (2015-06-13), pages 585 - 590 *
刘文主编: "《药用高分子材料学》", 中国中医药出版社, pages: 61 *
郑志华: "对乙酰氨基酚片脆碎度的研究", 《海峡药学》, vol. 19, no. 8, 31 December 2007 (2007-12-31), pages 20 - 21 *
陈茂棠等: "高含量对乙酰氨基酚直接可压性颗粒的制备", 《广东药学》 *
陈茂棠等: "高含量对乙酰氨基酚直接可压性颗粒的制备", 《广东药学》, no. 01, 31 December 2000 (2000-12-31), pages 29 - 30 *

Also Published As

Publication number Publication date
BR112021026407A8 (pt) 2022-11-22
CO2021017722A2 (es) 2022-01-17
CA3143724A1 (en) 2020-12-30
KR20220027194A (ko) 2022-03-07
AU2020301401A1 (en) 2022-01-27
US20240156740A1 (en) 2024-05-16
JP2022540348A (ja) 2022-09-15
PH12021553169A1 (en) 2022-08-15
BR112021026407A2 (pt) 2022-02-08
MX2021016089A (es) 2022-04-25
WO2020263947A1 (en) 2020-12-30
AU2020301401B2 (en) 2023-12-21
JP2025134843A (ja) 2025-09-17
IL288989A (en) 2022-02-01
JP7703220B2 (ja) 2025-07-07
US11918693B2 (en) 2024-03-05
US20250302754A1 (en) 2025-10-02
EP3989944A1 (en) 2022-05-04
AU2024200875A1 (en) 2024-02-29
US20200405645A1 (en) 2020-12-31

Similar Documents

Publication Publication Date Title
JP6325627B2 (ja) 口腔内崩壊錠及びその製造方法
CN101257800B (zh) 包含法莫替丁和布洛芬的药物
US20250302754A1 (en) Novel ibuprofen and acetaminophen composition
KR101400064B1 (ko) 건식 직타 속붕괴성 정제
CN101005831A (zh) 包含普拉克索或其可药用盐的延长释放片剂
NZ536046A (en) High dosage tablet forms of imatinib mesylate
JPH10182436A (ja) 固形医薬製剤
JP5630943B2 (ja) 複合剤組成物
WO2016062182A1 (zh) 一种普瑞巴林缓释制剂
BR112016020877B1 (pt) Uso de ondansetron, uso de um núcleo compreendendo uma matriz polímera não iônica e comprimido
TWI478733B (zh) 突釋藥物釋放組合物
JPH083066A (ja) かぜ薬製剤
CN100448431C (zh) 一种用于治疗儿童感冒的氨酚麻美口腔崩解片及制备方法
JP5201837B2 (ja) 口腔内速崩壊錠
JP5226732B2 (ja) 催眠用圧縮成型製剤
CN1706385B (zh) 治疗季节性和常年性过敏性鼻炎的新组合物
JP2025081930A (ja) 錠剤、造粒粒子、造粒粒子の製造方法及び錠剤の製造方法
AU2007201830B2 (en) High drug load tablet
AU2006269894B2 (en) Medicaments containing famotidine and ibuprofen and administration of same
JP2004107258A (ja) 催眠用圧縮成型製剤
HU231592B1 (hu) Favipiravir tartalmú gyógyszerkészítmény, ennek előállítása és alkalmazása
CN101190206A (zh) 减少了对消化管的刺激性的口服固形组合物
HK1118208B (en) Oral solid composition reduced in stimulation to the gastrointestinal tract
TW201014616A (en) Miglitol medicine composition

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination